| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CEO | Intermin CEO
2 companies
Howard B Rosen last filed a Form 4 in June 2025, as Director at KALA. The filings on record cover 2 companies. Howard B Rosen's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 5,293 shares of TLPH. Net of sales, the TLPH filings show accumulation of 45,606 shares.
Howard B Rosen has 24 Form 4 filings on record from April 2015 to June 2025, across 2 companies: Kala Bio (KALA), 2017–2025; Director at Talphera (TLPH), 2015–2023.
The 40 reported transactions were 18 option or other derivative awards, 12 stock awards, 5 dispositions back to the company and 3 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $60K and no sales.
The largest open-market purchase was 10,206 shares of TLPH at an average $3.26 on May 13, 2016, about $33K.
Shares as reported in the last Form 4 for each company; the most recent is from June 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.